Cordio Medical, a NYC-based medical speech processing platform provider, raised $18m in funding.
Backers included Ceros Capital Markets, the investment banking division of Ceros Financial Services, and Peregrine Ventures.
The company intends to use the funds to support clinical studies, partnerships, operations, and R&D.
Led by Tamir Tal, CEO, and Eyal Lifschitz, Chairman, Cordio Medical develops and provides solutions for monitoring health conditions through a patient’s speech. Its technologies are based on true speech signal processing technology, unique to each patient, augmented with machine learning capabilities. A patient speaks into a smartphone app backed by proprietary algorithms that allow near real-time monitoring and early detection of condition deterioration. The system is patient-tailored, constantly learning the patient’s voice, and provides personalized, seamless, and effortless monitoring. Cordio Medical’s goal is to identify and mitigate condition worsening by helping physicians prevent patient deterioration and hospitalization while keeping the patient’s wellbeing at the core.
The ongoing retail and distribution (R&D) of current and future versions of HearO® and clinical operations will be in Israeland the EU. Cordio Medical seeks to go to market in the U.S. in early 2024 with final approval from the FDA.
FinSMEs
27/06/2022